546 related articles for article (PubMed ID: 23599896)
61. Replication protein A (RPA) hampers the processive action of APOBEC3G cytosine deaminase on single-stranded DNA.
Lada AG; Waisertreiger IS; Grabow CE; Prakash A; Borgstahl GE; Rogozin IB; Pavlov YI
PLoS One; 2011; 6(9):e24848. PubMed ID: 21935481
[TBL] [Abstract][Full Text] [Related]
62. The cytidine deaminases AID and APOBEC-1 exhibit distinct functional properties in a novel yeast selectable system.
Krause K; Marcu KB; Greeve J
Mol Immunol; 2006 Feb; 43(4):295-307. PubMed ID: 15963568
[TBL] [Abstract][Full Text] [Related]
63. Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.
Warren CJ; Westrich JA; Doorslaer KV; Pyeon D
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825669
[TBL] [Abstract][Full Text] [Related]
64. Crystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain.
Shi K; Carpenter MA; Kurahashi K; Harris RS; Aihara H
J Biol Chem; 2015 Nov; 290(47):28120-28130. PubMed ID: 26416889
[TBL] [Abstract][Full Text] [Related]
65. DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.
Naumann JA; Argyris PP; Carpenter MA; Gupta HB; Chen Y; Temiz NA; Zhou Y; Durfee C; Proehl J; Koniar BL; Conticello SG; Largaespada DA; Brown WL; Aihara H; Vogel RI; Harris RS
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298259
[TBL] [Abstract][Full Text] [Related]
66. Orthologous mammalian APOBEC3A cytidine deaminases hypermutate nuclear DNA.
Caval V; Suspène R; Vartanian JP; Wain-Hobson S
Mol Biol Evol; 2014 Feb; 31(2):330-40. PubMed ID: 24162735
[TBL] [Abstract][Full Text] [Related]
67. APOBEC3A damages the cellular genome during DNA replication.
Green AM; Landry S; Budagyan K; Avgousti DC; Shalhout S; Bhagwat AS; Weitzman MD
Cell Cycle; 2016; 15(7):998-1008. PubMed ID: 26918916
[TBL] [Abstract][Full Text] [Related]
68. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.
Love RP; Xu H; Chelico L
J Biol Chem; 2012 Aug; 287(36):30812-22. PubMed ID: 22822074
[TBL] [Abstract][Full Text] [Related]
69. The cytidine deaminase AID exhibits similar functional properties in yeast and mammals.
Rogozin IB; Pavlov YI
Mol Immunol; 2006 Mar; 43(9):1481-4. PubMed ID: 16219354
[TBL] [Abstract][Full Text] [Related]
70. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.
Leonard B; Hart SN; Burns MB; Carpenter MA; Temiz NA; Rathore A; Vogel RI; Nikas JB; Law EK; Brown WL; Li Y; Zhang Y; Maurer MJ; Oberg AL; Cunningham JM; Shridhar V; Bell DA; April C; Bentley D; Bibikova M; Cheetham RK; Fan JB; Grocock R; Humphray S; Kingsbury Z; Peden J; Chien J; Swisher EM; Hartmann LC; Kalli KR; Goode EL; Sicotte H; Kaufmann SH; Harris RS
Cancer Res; 2013 Dec; 73(24):7222-31. PubMed ID: 24154874
[TBL] [Abstract][Full Text] [Related]
71. Activation-induced cytidine deaminase acts on double-strand breaks in vitro.
Shen HM
Mol Immunol; 2007 Feb; 44(5):974-83. PubMed ID: 16697045
[TBL] [Abstract][Full Text] [Related]
72. Structural Analysis of the Active Site and DNA Binding of Human Cytidine Deaminase APOBEC3B.
Hou S; Silvas TV; Leidner F; Nalivaika EA; Matsuo H; Kurt Yilmaz N; Schiffer CA
J Chem Theory Comput; 2019 Jan; 15(1):637-647. PubMed ID: 30457868
[TBL] [Abstract][Full Text] [Related]
73. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
74. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
75. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Ng JCF; Quist J; Grigoriadis A; Malim MH; Fraternali F
Nucleic Acids Res; 2019 Feb; 47(3):1178-1194. PubMed ID: 30624727
[TBL] [Abstract][Full Text] [Related]
76. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
77. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
[TBL] [Abstract][Full Text] [Related]
78. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.
Mahieux R; Suspène R; Delebecque F; Henry M; Schwartz O; Wain-Hobson S; Vartanian JP
J Gen Virol; 2005 Sep; 86(Pt 9):2489-2494. PubMed ID: 16099907
[TBL] [Abstract][Full Text] [Related]
79. Mutating for Good: DNA Damage Responses During Somatic Hypermutation.
Pilzecker B; Jacobs H
Front Immunol; 2019; 10():438. PubMed ID: 30915081
[TBL] [Abstract][Full Text] [Related]
80. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types.
Jakobsdottir GM; Brewer DS; Cooper C; Green C; Wedge DC
BMC Biol; 2022 May; 20(1):117. PubMed ID: 35597990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
